Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Life sciences
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
About
Home
NICE guidance
In development
Guidance, NICE advice and quality standards
In development
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic selection
Filter
Skip to results
Filter by title or keyword
Filter
Expected publication date
Expected publication date
From date
To date
Apply date filters
Area of interest
Area of interest
COVID-19 (7)
Type
Type
Guidance (402)
NICE advice (1)
Quality standard (10)
Guidance programme
Guidance programme
Clinical guidelines (28)
Diagnostics guidance (10)
Health technology evaluations (14)
Highly specialised technologies guidance (9)
Interventional procedures guidance (12)
Medical technologies guidance (11)
NICE guidelines (31)
Public health guidelines (1)
Technology appraisal guidance (323)
Advice programme
Advice programme
Medtech innovation briefings (1)
Apply filters
Showing 271 to 280 of 413
Sort by
Title
Date
Apply sorting
Guidance, NICE advice and quality standards in development
Title
Type
Expected publication date
Palovarotene for treating flare ups of heterotopic ossification associated with fibrodysplasia ossificans progressiva [ID2721]
Highly specialised technology
TBC
Parsaclisib for treating relapsed or refractory marginal zone lymphoma [ID3976]
Technology appraisal guidance
TBC
Peezy Midstream for urine collection (MT446)
Medical technologies guidance
TBC
Pegcetacoplan for amyotrophic lateral sclerosis TS ID 10594
Technology appraisal guidance
TBC
Pegcetacoplan for treating geographic atrophy [ID4041]
Technology appraisal guidance
TBC
Pegylated liposomal irinotecan in combination for untreated metastatic pancreatic cancer [ID6461]
Technology appraisal guidance
TBC
Pegzilarginase for treating arginase-1 deficiency [ID4029]
Highly specialised technology
30 October 2024
Pembrolizumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID5094]
Technology appraisal guidance
16 October 2024
Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer [ID3907]
Technology appraisal guidance
16 October 2024
Pembrolizumab with chemoradiation for untreated high-risk locally advanced cervical cancer [ID6138]
Technology appraisal guidance
TBC
Previous page
1
…
26
27
Current page
28
29
30
…
42
Page
28
of
42
Next page
Results per page
10
25
50
All
Back to top